Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 136

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 136
---
 adjusted cash and cash equivalents and marketable securities, additional paid-incapital, total stockholders’ equity and total capitalization by approximately $14.0 million, assuming an initial public offering price of $15.00, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Pursuant to our current certificate of incorporation, the conversion price of the Series C convertible preferred stock will be adjusted as a result of this offering. The current conversion price is $41.8311. Applying the formula set forth in our amended and restated certificate of incorporation for issuances of our common stock below the current conversion price and partially waived anti-dilution adjustments by the holders of our Series C convertible preferred stock, the conversion price of the Series C convertible preferred stock will be adjusted to $36.5499 as a result of this offering, based upon an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. A $1.00 decrease in the initial public offering price would increase the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 19,731 shares, and a $1.00 increase in the initial public offering price would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 19,254 shares; provided, however, that in no event would the shares of our Series C convertible preferred stock outstanding prior to the Stock Split convert into more than 3,049,156 shares of our common stock upon the closing of this offering. A 1.0 million share increase in the size of this offering would increase the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,261 shares, and a 1.0 million share decrease in the size of this offering would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,795 shares. The pro forma and pro forma as adjusted information are illustrative only and following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. 90

You should read this information in conjunction with our financial statements and the related notes included elsewhere in this prospectus, the section of this prospectus titled “